Medtronic PLC Valuation – January 2019 $MDT

Company Profile (excerpt from Reuters): Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. Its Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. Its Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. Its Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.


Downloadable PDF version of this valuation:

ModernGraham Valuation of MDT – January 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $118,362,552,161 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 2.56 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 4.53% Fail
6. Moderate PEmg Ratio PEmg < 20 28.33 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.41 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 2.56 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.79 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $3.11
MG Growth Estimate 0.94%
MG Value $32.29
Opinion Overvalued
MG Grade B
MG Value based on 3% Growth $45.11
MG Value based on 0% Growth $26.45
Market Implied Growth Rate 9.91%
Current Price $88.13
% of Intrinsic Value 272.93%

Medtronic PLC is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings growth over the last ten years, and the high PEmg ratio. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $2.93 in 2015 to an estimated $3.11 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 9.91% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Medtronic PLC revealed the company was trading above its Graham Number of $60.27. The company pays a dividend of $1.84 per share, for a yield of 2.1%, putting it among the best dividend paying stocks today. Its PEmg (price over earnings per share – ModernGraham) was 28.33, which was below the industry average of 52.7, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-12.33.

Medtronic PLC performs fairly well in the ModernGraham grading system, scoring a B.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$12.33
Graham Number $60.27
PEmg 28.33
Current Ratio 2.56
PB Ratio 2.41
Current Dividend $1.84
Dividend Yield 2.09%
Number of Consecutive Years of Dividend Growth 20

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 10/1/2018
Total Current Assets $21,653,000,000
Total Current Liabilities $8,463,000,000
Long-Term Debt $23,663,000,000
Total Assets $88,150,000,000
Intangible Assets $59,424,000,000
Total Liabilities $38,436,000,000
Shares Outstanding (Diluted Average) 1,360,900,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $4.31
Apr2018 $2.27
Apr2017 $2.89
Apr2016 $2.48
Apr2015 $2.41
Apr2014 $3.02
Apr2013 $3.37
Apr2012 $3.41
Apr2011 $2.86
Apr2010 $2.79
Apr2009 $1.84
Apr2008 $1.95
Apr2007 $2.41
Apr2006 $2.09
Apr2005 $1.48
Apr2004 $1.60
Apr2003 $1.30
Apr2002 $0.80
Apr2001 $0.85
Apr2000 $0.89
Apr1999 $0.39

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $3.11
Apr2018 $2.55
Apr2017 $2.73
Apr2016 $2.75
Apr2015 $2.93
Apr2014 $3.15
Apr2013 $3.10
Apr2012 $2.83
Apr2011 $2.49
Apr2010 $2.27
Apr2009 $1.99
Apr2008 $2.01
Apr2007 $1.96
Apr2006 $1.64
Apr2005 $1.34
Apr2004 $1.21
Apr2003 $0.96

Recommended Reading:

Other ModernGraham posts about the company

Medtronic PLC Valuation – March 2018 $MDT
Medtronic PLC Valuation – July 2016 $MDT
Medtronic PLC Valuation – January 2016 Update $MDT
Medtronic PLC Valuation – October 2015 Update $MDT
Medtronic Inc. Analysis – July 2015 Update $MDT

Other ModernGraham posts about related companies

UnitedHealth Group Inc Valuation – November 2018 $UNH
Luminex Corp Valuation – October 2018 $LMNX
LHC Group Inc Valuation – September 2018 $LHCG
Chartwell Retirement Residences Valuation – August 2018 $TSE:CSH.UN
STERIS PLC Valuation – August 2018 $STE
CryoLife Inc Valuation – August 2018 $CRY
Charles River Laboratories International Inc Valuation – August 2018 $CRL
Surmodics Inc Valuation – August 2018 $SRDX
Conmed Corp Valuation – August 2018 $CNMD
Invacare Corp Valuation – July 2018 $IVC


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.